This makes KIT an attractive target for NB therapy, since several drugs, which can target KIT are used for chronic myeloid leukemia (CML), gastrointestinal stromal tumors (GIST) and kidney cancers [20]. This evidence concerns the gene KIT and chronic myelogenous leukemia, BCR-ABL1 positive.